Is there enough evidence now to use injectable semaglutide as a foundational therapy for symptomatic heart failure with preserved ejection fraction in the setting of overweight or obesity?
Answer from: at Academic Institution
While the evidence for using injectable semaglutide in the setting of heart failure with preserved ejection fraction (HFpEF) and overweight/obesity is promising, it's still considered emerging!
STEP-HFpEF trial: This large, well-designed study showed that semaglutide significantly improve...
Comments
at Yale Medicine Well outlined Dr. @Albulushi. I would only add tha...
Well outlined Dr. @Albulushi. I would only add tha...